Bioavailability and bioequivalence requirements in the European community

Area of Science:

• Pharmaceutical Sciences
• Regulatory Affairs
• Drug Development

Background:

• The European Commission (EC) has issued a new Note for Guidance concerning bioavailability and bioequivalence for regulatory consultation.
• This updated guidance supersedes the 1984 version, providing enhanced regulatory detail.
• A separate EC Note for Guidance on modified-release products, effective since July 1990, is also under discussion.

Purpose of the Study:

• To provide a comparative overview of the new EC Note for Guidance on bioavailability and bioequivalence.
• To highlight the increased regulatory detail in the new guidance compared to the 1984 version.
• To discuss the EC Note for Guidance on modified-release products and its emphasis on clinical aspects.

Main Methods:

• Comparative analysis of the new EC Note for Guidance with the previous version.
• Review of regulatory details and expected implementation timeline.
• Examination of the EC Note for Guidance on modified-release products, focusing on its clinical considerations.

Main Results:

• The new EC Note for Guidance offers significantly more regulatory detail than its 1984 predecessor.
• The guidance is anticipated to be implemented in 1991, with potential minor revisions.
• The guidance for modified-release products emphasizes clinical justification, distinguishing it globally.

Conclusions:

• The updated EC guidance enhances regulatory clarity for bioavailability and bioequivalence studies.
• The focus on clinical justification for modified-release products represents a significant advancement in regulatory science.
• Stakeholders are encouraged to review the draft guidance during the consultation period.